The phase 3 VOLGA trial looks at perioperative durvalumab plus enfortumab vedotin, with and without tremelimumab, for muscle-invasive bladder cancer.

Adding tarlatamab to durvalumab as first-line maintenance therapy in patients with extensive-stage small cell lung cancer improved overall survival by more than 8 months. Patients who received the ...

An individualized mRNA-based cancer vaccine reduces melanoma recurrence and distant metastasis when added to immunotherapy, marking a potential milestone for personalized cancer treatment.

Everyday medical equipment is shedding micro- and nanoplastics into patients, bypassing their bodies’ natural filters and ...

Phase 3 trials for three different agents show substantial reductions in kidney function decline and other improvements ...

Energy drink use in adolescents may be a marker of sleep debt, and clinicians should treat it as a cue to screen for short ...

Upadacitinib, a JAK1 inhibitor, is linked to a lower risk for treatment failure and more steroid-free disease stability than ...

A pooled phase 3 analysis shows that 15-mg and 20-mg doses of estetrol both reduce the frequency and severity of ...

Synthesizing medical management strategies with surgical and interventional treatments improves outcomes in patients with ...

Compared with the traditional diet, the low-carbohydrate diet reduced insulin requirements by 0.08 IU/kg, or 7.4 IU/d, and ...

As cases rise in that state, CDC shares tips with clinicians on how to recognize and treat the mosquito-borne virus.

Intracranial stenting after failed endovascular thrombectomy is linked to improved outcomes in patients with acute ischemic ...